Core Viewpoint - The company reported a decline in overall revenue and net profit for the first three quarters of 2025, but showed signs of recovery in Q3, particularly in domestic operations and overseas growth [1][2]. Group 1: Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.287 billion yuan, a year-on-year decrease of 7.69%, and a net profit attributable to shareholders of 60 million yuan, down 72.36% year-on-year [1]. - In Q3 2025, the company recorded a revenue of 478 million yuan, representing a year-on-year increase of 10.25%, while the net profit attributable to shareholders was 34 million yuan, down 25.12% year-on-year [1]. Group 2: Domestic and Overseas Performance - Domestic revenue for the main business was 1.074 billion yuan, a year-on-year decrease of 5.9%, while overseas business saw a significant growth with a revenue of 208 million yuan, up 39% year-on-year [2]. - In Q3 2025, domestic main business revenue reached 403 million yuan, a year-on-year increase of 14.4%, with overseas revenue growing by 68.5% year-on-year [2]. Group 3: Equipment Installation and Market Expansion - The company installed 1,806 new light-emitting devices in the first three quarters of 2025, with a total installation exceeding 12,410 units [3]. - The company’s unique pipeline products have gained recognition, with a specific diagnostic reagent entering the industrialization phase [3]. Group 4: Profit Forecast - The company forecasts total revenues of 1.885 billion yuan, 2.173 billion yuan, and 2.546 billion yuan for 2025-2027, with respective year-on-year growth rates of -6.29%, 15.29%, and 17.17% [4]. - The projected net profit attributable to shareholders for the same period is 119 million yuan, 291 million yuan, and 407 million yuan, with year-on-year growth rates of -60.61%, 144.63%, and 40.19% [4].

Core Perspective - Shenzhen has developed a vibrant economy over 45 years, driven by a spirit of innovation and collaboration among over 580 listed companies, which have significantly contributed to the city's growth [12][13]. Group 1: Pursuit of Excellence - Mindray Medical has become a leader in the medical device industry, emphasizing the importance of innovation and a strong technological foundation, with over 10% of revenue allocated to R&D, amounting to over 4 billion yuan in 2024 [13][14]. - The company has successfully developed several pioneering medical devices, filling gaps in domestic technology and expanding into international high-end markets [14][15]. Group 2: Daring to Explore - Hytera, originally founded as a small trading company, has transformed into a major player in specialized communication, driven by a willingness to innovate and adapt to market demands [16][17]. - The company has expanded its operations internationally and has focused on developing proprietary technology to compete against global giants [17][18]. Group 3: Openness and Inclusiveness - BGI, a leading player in gene technology, relocated to Shenzhen in 2007, benefiting from the city's open and innovative environment, which has facilitated its growth from a research institution to a global leader [20][21]. - The company has successfully developed non-invasive prenatal genetic testing technology, significantly impacting public health services in Shenzhen [22][23]. Group 4: Practicality and Rule of Law - Bawoo Storage has thrived in Shenzhen's market-oriented environment, focusing on semiconductor storage solutions and adapting quickly to market trends, which has led to its successful IPO on the STAR Market [25][26]. - The company has leveraged local venture capital support to navigate industry challenges and has established itself as a key player in the storage industry [26][27]. Group 5: Innovation and Development - Aihuilong has emerged as a leader in the in-vitro diagnostic field, achieving significant technological breakthroughs and expanding its product offerings to cover various medical areas [27][28]. - The company has introduced innovative logistics solutions and is actively pursuing international market expansion, with products available in over 120 countries [30].

亚辉龙此次发布的联合创新成果射血分数保留型心力衰竭（HFpEF）诊断试剂，让亚辉龙在心血管疾病 领域更进一步，在代谢组学检测领域取得关键突破，心肌标志物检测矩阵从传统的心肌损伤（hs- cTnI）、心功能评估（BNP/NT-proBNP）扩展到能量代谢监测维度。 值得注意的是，亚辉龙在IVD（体外诊断）行业精耕细作十七年，高度重视心血管疾病领域布局，公司 构建了多个核心技术平台。其中微流控化学发光技术作为"十四五"国家重点研发计划的核心攻关方向， 可实现15分钟内完成多个心血管项目的全血联检，为胸痛中心等急救场景提供黄金时间窗口。 BCAA/BCKA生化检测体系的加入，使生化检测平台与现有免疫检测平台形成互补，配合超声等影像学 检查，最终构建起"影像结构评估+生物标志物功能检测+代谢动态监测"的三维诊疗体系。 业内人士表示："心衰作为心血管疾病的终末战场，治疗缺口巨大。当前国内药物市场规模仅约100亿 元，但创新药械正以超50%的增速打开空间。"HFpEF诊断试剂不仅填补了全球HFpEF特异性体外诊断 领域的技术空白，重塑心衰疾病筛查、诊断乃至慢病管理的现有模式，更凭借其临床价值与商业潜力， 为体外诊断赛道注 ...

值得注意的是，亚辉龙在IVD（体外诊断）行业深耕细作十七年，高度重视心血管疾病领域布局，公司 构建了多个核心技术平台。其中微流控化学发光技术作为"十四五"国家重点研发计划的核心攻关方向， 可实现15分钟内完成多个心血管项目的全血联检，为胸痛中心等急救场景提供黄金时间窗口。 BCAA/BCKA生化检测体系的加入，使生化检测平台与现有免疫检测平台形成互补，配合超声等影像学 检查，最终构建起"影像结构评估+生物标志物功能检测+代谢动态监测"的三维诊疗体系。 （文章来源：证券时报网） 与射血分数降低型心力衰竭（HFrEF）不同，HFpEF患者因心肌结构与功能改变更隐蔽，传统诊断手段 长期面临"瓶颈"——超声心动图操作依赖经验、生物标志物（如BNP/NT-proBNP）特异性不足，导致临 床漏诊率高达30%—70%，多数患者确诊时已进入中晚期，治疗难度与医疗成本显著上升。 近日，"高性能免疫现场快速检测系统研发项目会议暨BCAA、BCKA创新成果发布"在南京隆重举行。 会议上，亚辉龙（688575.SH）与新加坡国立大学心血管中心的王义斌教授联合宣布，全球首个基于支 链氨基酸/支链α酮酸（BCAA/BCKA）检测的射血 ...